Stock Events

Stock Events

Immix Biopharma 

$13.83
34
-$0.13-0.93% Thursday 20:00
+$0.00+0%Thursday 23:30After hours

Statistics

Day High
13.82
Day Low
13.79
52W High
15.1
52W Low
1.94
Volume
39,166
Avg. Volume
-
Mkt Cap
984.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.24
-0.21
-0.18
-0.15
Expected EPS
-0.187143
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-29.44MNet Income

Analyst Ratings

22.33Average Price Target
The highest estimate is 27.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMMX. It's not an investment recommendation.
PayPal
5
PYPL
Amazon
4
AMZN
NVIDIA
4
NVDA
AMD
4
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, directly competing in the biopharma space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for the treatment of serious diseases, overlapping with Immix's therapeutic areas.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the same innovative drug development space as Immix.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation specializes in the discovery, development, and commercialization of proprietary therapeutics, directly competing with Immix in the oncology and inflammation markets.
Exelixis
EXEL
Mkt Cap13.49B
Exelixis, Inc. is a biotechnology company that develops and sells small molecule therapies for the treatment of cancer, competing in the oncology space with Immix.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, a large pharmaceutical company, competes across a broad range of therapeutic areas, including those targeted by Immix Biopharma.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, directly competing with Immix.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is one of the world's leading biotechnology companies, focusing on areas such as oncology/hematology, cardiovascular disease, and more, competing across several therapeutic areas with Immix.

About

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Show more...
CEO
Ilya Rachman
Employees
21
Country
United States
ISIN
US45258H1068

Listings

BOATS
BOATS
IMMX.BOATS
XNAS
US
IMMX

0 Comments

Share your thoughts

FAQ

What is Immix Biopharma stock price today?▼
The current price of IMMX is $13.83 USD — it has decreased by -0.93% in the past 24 hours. Watch Immix Biopharma stock price performance more closely on the chart.
What is Immix Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immix Biopharma stocks are traded under the ticker IMMX.
Is Immix Biopharma stock price growing?▼
IMMX stock has fallen by -0.79% compared to the previous week, the month change is a +48.23% rise, over the last year Immix Biopharma has showed a +531.51% increase.
What is Immix Biopharma market cap?▼
Today Immix Biopharma has the market capitalization of 984.56M
When is the next Immix Biopharma earnings date?▼
Immix Biopharma is going to release the next earnings report on December 02, 2026.
What is Immix Biopharma revenue for the last year?▼
Immix Biopharma revenue for the last year amounts to 0 USD.
What is Immix Biopharma net income for the last year?▼
IMMX net income for the last year is -29.44M USD.
How many employees does Immix Biopharma have?▼
As of September 04, 2026, the company has 21 employees.
In which sector is Immix Biopharma located?▼
Immix Biopharma operates in the Health & Wellness sector.
When did Immix Biopharma complete a stock split?▼
Immix Biopharma has not had any recent stock splits.
Where is Immix Biopharma headquartered?▼
Immix Biopharma is headquartered in LOS ANGELES, United States.